J. Bacik

发表

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.

R. Motzer, J. Bacik, T. Mariani, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Methods for categorizing a prognostic variable in a multivariable setting

Madhu Mazumdar, J. Bacik, M. Mazumdar, 2003, Statistics in medicine.

A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma

L. Schwartz, J. Bacik, R. Motzer, 2006, Investigational New Drugs.

Presentation and subsequent publication rates of phase I oncology clinical trials

J. Bacik, D. Spriggs, A. Cheung, 2005, Cancer.

Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors

J. Bacik, V. Reuter, M. Mansukhani, 2004, Molecular Cancer.

A brief symptom index for advanced renal cell carcinoma

R. Motzer, J. Bacik, D. Cella, 2006, Health and quality of life outcomes.

Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy.

J. Bacik, R. Motzer, D. Bajorin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma

R. Motzer, J. Bacik, P. Russo, 2003, Investigational New Drugs.

Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.

J. Bacik, M. Mazumdar, H. Scher, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Development of a Validated Instrument to Evaluate Bowel Function After Sphincter-Preserving Surgery for Rectal Cancer

J. Bacik, H. Thaler, J. Guillem, 2005, Diseases of the colon and rectum.

Sequential dose-intensive paclitaxel plus ifosfamide and carboplatin plus etoposide with autologous stem cell transplantation for germ cell tumor (GCT) patients (pts)

M. Bains, J. Bacik, R. Motzer, 2005 .

Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.

M. Bains, R. Motzer, J. Bacik, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.

J. Bacik, R. Motzer, D. Bajorin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.

J. Bacik, T. Mariani, M. Mazumdar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.

M. Bains, J. Bacik, M. Mazumdar, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Salvage chemotherapy for patients with advanced pure seminoma.

J. Bacik, M. Mazumdar, V. Reuter, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome.

J. Bacik, R. Motzer, D. Bajorin, 2003, Urology.

Testicular Seminoma: A Clinicopathologic and Immunohistochemical Study of 105 Cases with Special Reference to Seminomas with Atypical Features

J. Bacik, M. Mazumdar, V. Reuter, 2002, International journal of surgical pathology.

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

R. Motzer, J. Bacik, P. Russo, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

M Mazumdar, R. Motzer, J. Bacik, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum.

M. Bains, R. Motzer, J. Bacik, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel, I fosfamide, a nd C isplatin S econd-Line T herapy for P atients W ith R elapsed T esticular G erm C ell C ancer

M. Bains, R. Motzer, J. Bacik, 2000 .

Reoperative RPLND for germ cell tumor; initial presentation, complications and outcome

J. Bacik, R. Motzer, D. Bajorin, 2001 .

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

R. Motzer, J. Bacik, M. Mazumdar, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.

R. Motzer, J. Bacik, M. Mazumdar, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib in patients with metastatic renal cell carcinoma.

R. Motzer, J. Bacik, M. Michaelson, 2006, JAMA.

Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor.

J. Bacik, M. Mazumdar, V. Reuter, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

L. Schwartz, R. Motzer, J. Bacik, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.

J. Bacik, R. Motzer, D. Bajorin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

L. Schwartz, R. Motzer, J. Bacik, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interferon-Alfa a s a C omparative T reatment f or C linical Trials o f N ew T herapies A gainst A dvanced R enal Cell C arcinoma

R. Motzer, J. Bacik, P. Russo, 2002 .

Survival a nd P rognostic S tratification o f 6 70 P atients With A dvanced R enal C ell C arcinoma

R. Motzer, J. Bacik, M. Mazumdar, 1999 .

Phase II trial of thalidomide for patients with advanced renal cell carcinoma.

R. Motzer, J. Bacik, P. Russo, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment outcome for metastatic papillary renal cell carcinoma patients

R. Motzer, J. Bacik, P. Russo, 2006, Cancer.

Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma.

R. Motzer, J. Bacik, P. Russo, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma

L. Schwartz, J. Bacik, P. Russo, 2008, Investigational New Drugs.

Phase II trial of bortezomib for patients with advanced renal cell carcinoma.

L. Schwartz, R. Motzer, J. Bacik, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma

R. Motzer, J. Bacik, M. Mazumdar, 2004, Clinical Cancer Research.

The functional assessment of cancer therapy–BRM (FACT–BRM): A new tool for the assessment of quality of life in patients treated with biologic response modifiers

R. Motzer, J. Bacik, T. Mariani, 2004, Quality of Life Research.

Outcome o f P ostchemotherapy S urgery A fter T reatment With M ethotrexate, V inblastine, D oxorubicin, and C isplatin i n P atients W ith U nresectable or M etastatic T ransitional C ell C arcinoma

J. Bacik, M. Mazumdar, H. Scher, 1999 .

Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB.

M Mazumdar, R. Motzer, J. Bacik, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors

L. Schwartz, J. Bacik, M. Mazumdar, 2004, Investigational new drugs.